WASHINGTON (AP) — A panel of Food and Drug Administration experts again rejected Johnson & Johnson’s bid to expand use of its blood thinner Xarelto to reduce dangerous blood clots in a new group of patients, those with acute coronary artery disease.

Recommended Stories

Kratom, a possible heroin treatment, faces unclear fate after FDA warning

FDA warns of problems with Philips heart devices

Pro-life activists skeptical of FDA abortion pill study